GlassScriptPhysician profile
Brandy L Yarbrough
NPI 1275766545
$5,325.39
in general payments reported to CMS, 2019-2025
32 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $597 · 2023: $1,508 · 2024: $1,567 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,478 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.96 |
| Education | $109.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,165.02 | 2021-2025 | |
| Janssen Biotech, INC. | $661.27 | 2022-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $492.36 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $443.58 | 2022-2025 | Entyvio, Glassia, Eohilia |
| Ardelyx, INC. | $374.37 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $342.67 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $205.76 | 2022-2024 | Dificid, Zerbaxa |
| Regeneron Healthcare Solutions, INC. | $170.97 | 2023-2025 | Dupixent |
| Celgene Corporation | $150.55 | 2022-2024 | Zeposia |
| Evoke Pharma, INC. | $141.94 | 2021-2024 | Gimoti |
| Glaxosmithkline, LLC. | $134.18 | 2023 | Arexvy, Trelegy Ellipta, Nucala |
| Ironwood Pharmaceuticals, INC | $119.18 | 2021-2025 | Linzess |
| Medtronic, INC. | $103.57 | 2025 | Interstim |
| Phathom Pharmaceuticals, INC. | $87.65 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $78.65 | 2024-2025 | Iqirvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $77.07 | 2024-2025 | Zenpep |
| Organon LLC | $65.55 | 2023-2024 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $65.52 | 2022-2024 | |
| Pfizer INC. | $60.93 | 2024-2025 | |
| Lilly USA, LLC | $59.50 | 2025 | Omvoh |
| Enterra Medical, INC. | $54.39 | 2025 | |
| Grifols USA, LLC | $44.21 | 2024-2025 | Prolastin-C Liquid |
| Qol Medical, LLC | $29.60 | 2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $29.19 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $25.98 | 2021 | |
| Baxter Healthcare | $25.21 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Madrigal Pharmaceuticals | $22.75 | 2025 | Rezdiffra |
| Verona Pharma, INC. | $22.69 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.57 | 2025 | |
| Vifor Pharma, INC. | $18.15 | 2024 | Zemaira |
| Gilead Sciences, INC. | $17.39 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.97 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Yarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.